Pavankumar Asalapuram

Pavankumar Asalapuram

Affiliated to Research
Visiting address: Widerströmska huset Tomtebodavägen 18 A, plan 3, 17165 Solna
Postal address: K9 Global folkhälsa, K9 GPH Stålsby Lundborg, 171 77 Stockholm

About me

  • I am focused on developing innovative, simple-to-use diagnostic methods and tools for infectious diseases, especially for detecting and preventing nosocomial (hospital-acquired) and drug-resistant zoonotic community-spread infections. With a PhD in Biotechnology and a background in Pharmacy, I have published 15 peer-reviewed scientific articles, hold four patent families, and delivered over 40 conference/oral presentations. My research interests span point-of-care molecular diagnostics targeting antibiotic resistance and biofilms, lateral flow biosensors, alongside learning and developing AI-driven strategies within life sciences and global public health.

     

  • Driven by a passion for applying fundamental knowledge to create impactful solutions, I transitioned into entrepreneurship. I successfully secured approximately EUR 19 million in investment and grants, established ISO 13485-certified production facilities, and led large teams. I have led teams in multi-country clinical evaluations of in vitro molecular diagnostic (IVD) test kits for multidrug-resistant tuberculosis (MDR-TB), successfully completing these studies. These efforts have led to the commercialization and market introduction of diagnostic platforms, test kits, and other products. I am proud that a start-up I co-founded became the first-ever company to receive both EIC and BMGF grants.

     

  • Throughout my journey, I have coordinated or played key roles in multi-country projects funded by the European Innovation Council (H2020 SME1, EIC-Accelerator, INNOVA4TB, COST, MSCA4Ukraine), the Indo-Swedish initiative (Vinnova, DBT, SAMRIDH, CATALYST), and the USA (Bill and Melinda Gates Foundation). I remain focused on advancing healthcare innovations and building a strong network of collaborations to improve global healthcare systems and quality of life, supporting the One Health initiative to achieve Sustainable Development Goals (SDGs).

Research

  • Antibiotic resistant microbes and biofilms, Molecular diagnostics, Antigen-antibody based lateral flow and ELISA assays, Global public health.

Teaching

  • Supervised around 20 Bachelors and Masters thesis students/projects.

    Conducted laboratory practical classess for Bachelor and Masters degree students. 

  •  

Articles

All other publications

  • Patent: 2024
    Novel coating and immobilization buffer for antigens and antibodies and uses thereof
    Asalapuram P; Nikhil S
  • Patent: 2022
    Modified Shigella apyrase and uses thereof
    Asalapuram P; Nikhil S
  • Patent: 2017
    Diagnostic device and related method
    Asalapuram P; Mats NB
  • Patent: 2016
    Analytical and diagnostic methods utilizing Shigella flexneri apyrase
    Asalapuram P; Aman R
  • Patent: 2009
    A method to detect the microbial resistance to antibiotics using fluorescence
    Asalapuram P; Krishnan S; Alagumaruthanayagam A
  • Review: FOOD TECHNOLOGY AND BIOTECHNOLOGY. 2008;46(2):125-145
    The Need and New Tools for Surveillance of Escherichia coli Pathogens
    Asalapuram P; Krishnan Sankaran
  • Report: 2005;:26
    Characterization of diarrhoeagenic E. coli (EPEC and EHEC) from incidences of infantile diarrhoea
    Asalapuram P

Grants

  • Exploring mlfoDx MDR-TB diagnostic platform in Africa and Latin American markets
    Business Sweden
    1 November 2023
  • Rapid Affordable Reliable-ELISA (RAR-ELISA) platform for the diagnosis of important helminthic infections
    Department of Biotechnology , Ministry of Science and Technology
    1 June 2023 - 31 December 2024
  • Multiplex Diagnostic Platform for Accurate and Rapid Detection of MDR & pre-XDR-TB
    IPE Global
    1 January 2023
  • Adaptable multi-flow diagnostics for multidrug-resistant TB using tongue swabs
    Bill and Melinda Gates Foundation
    1 November 2022
  • AdvanceTB: Towards an improvement in diagnostics and treatment strategies for tuberculosis control
    1 September 2022 - 30 September 2026
  • mfloDx: An Adaptable Multiflow Diagnostic Platform to Genetically Identify Drug Resistant Infection
    European Commission Directorate-General for Research and Innovation
    1 January 2020 - 30 June 2024
  • mfloDx: An Adaptable Multiflow Diagnostic Platform to Genetically Identify Drug Resistant Infection
    European Commission Directorate-General for Research and Innovation
    1 October 2019 - 29 February 2020
  • RCA-ADT diagnostic platform for the rapid detection of enteric pathogens
    EPSRC grant
    1 January 2016 - 31 December 2017
  • A multiplex diagnostic test for multi-drug/extensively drug-resistant tuberculosis
    VINNOVA
    1 November 2013 - 30 September 2016
  • Integrated fluidic-array-microsystem for rapid screening of extended spectrum β-lactamases and multidrug resistant pathogens.
    KTH - Life Science Platform
  • Real-time wireless biosensor networks for the surveillance of microbes and pollutants in drinking water supply lines
    KTK Life Science Technology Platform
  • INNOVA4TB: Innovative development to enable individualised tuberculosis treatment
    European Commission Directorate-General for Research and Innovation

Employments

  • Affiliated to Research, Department of Global Public Health, Karolinska Institutet, 2022-2026
  • CEO, Mitti Lifetek AB, 2019-2024
  • Founder & CEO, EMPE Diagnostics AB, 2016-2024
  • Postdoctor, Stockholm University, 2013-2016
  • Researcher, Biothema AB & KTH, 2012-2013
  • Postdoctor, Molecular Diagnostics, Royal Institute of Technology, 2010-2011

Degrees and Education

  • PhD, Clinical Biotechnology, Anna University, Chennai, 2010
  • M.S. (res), Clinical Biotechnology, Anna University, Chennai, 2006
  • EPGD in Hospital & Health Care Management, Loyola Institute of Business Administration (LIBA), 2002
  • B. Pharmacy, Pharmacy, Madras Medical College, Dr MGR Medical University, 2001

News from KI

Events from KI